Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
December 23, 2020 16:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
December 11, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of...
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
December 08, 2020 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single...
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
November 25, 2020 07:00 ET
|
Altimmune, Inc.
Simple, single-dose nasal spray offers greater ease and comfort of administration; positioning AdCOVID as a differentiated vaccine candidate for adults and children AdCOVID is capable of stimulating...
Altimmune to Present at Upcoming Virtual Investor Conferences
November 16, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for...
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
November 10, 2020 01:00 ET
|
Altimmune, Inc.
AdCOVID, a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity Lonza Agreement...
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
November 09, 2020 16:05 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended...
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
November 03, 2020 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial...
Altimmune to Present at Two Upcoming Virtual Investor Conferences
October 15, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for...
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate
October 12, 2020 07:01 ET
|
Altimmune, Inc.
Comprehensive analysis shows AdCOVID uniquely stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract Nasal mucosal...